• Publications
  • Influence
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor. Expand
Clopidogrel with or without omeprazole in coronary artery disease.
The results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI, but the two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole. Expand
Bleeding peptic ulcer.
Although hospitalization and surgery for uncomplicated ulcers have decreased in the United States and Europe over the past 20 to 30 years, the number of hospital admissions for hemorrhage associated with ulcers has remained relatively unchanged. Expand
SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease.
This research presents a novel and scalable approach to personalized Gastroenterology that aims to provide real-time information about the progression of Graves' disease and its Kessler's disease progression. Expand
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a
Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs. Expand
Gastric mucosal defense and cytoprotection: bench to bedside.
Conditions in which mucosal injury is directly related to impairment in mucosal defense are discussed, focusing on disorders with important clinical sequelae: nonsteroidal anti-inflammatory drug (NSAID)-associated injury, which is primarily related to inhibition of cyclooxygenase-mediated PG synthesis, and stress-related mucosal disease (SRMD), which occurs with local ischemia. Expand
Management of Patients With Ulcer Bleeding
This guideline presents recommendations for the step-wise management of patients with overt upper gastrointestinal bleeding, and patients with established cardiovascular disease who require aspirin should start PPI and generally re-institute aspirin soon after bleeding ceases. Expand
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making. Expand
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
  • L. Laine
  • Medicine
  • Gastroenterology
  • 1 February 2001
The risks of clinical GI disease in NSAID users, the predictors of increased risk, and strategies for prevention of NSAID-associated GI disease are discussed. Expand
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the
The ACCCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines focused on reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Expand